ArticleTransplant infectious disease : an official journal of the Transplantation Society
Screening and Reactivation of Chagas Disease Among Solid Organ Transplant Candidates and Recipients: A 10-Year Single Center Experience in Florida.
Article in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChagas disease (CD), a neglected tropical disease usually associated with Latin America, is increasingly recognized as an emerging infection in the United States. Screening for CD is recommended for solid organ transplant (SOT) candidates with epidemiologic risk factors; however, data on prevalence and post-transplant reactivation in the United States remain limited.
methodsWe conducted a retrospective cohort study of SOT candidates and recipients screened for T. cruzi at a large transplant center in Miami, Florida. Demographics, clinical characteristics, and 2-year outcomes of recipients with CD were analyzed.
resultsBetween August 1, 2013, and August 1, 2023, 6021 SOTs were performed. 1898 candidates (31%) were screened, and 21 (1.1%) tested positive for T. cruzi, of whom 10 were SOT recipients. All seropositive recipients were born in historically endemic areas. Median post-transplant surveillance was 13.5 (range 1-25) months. Seven patients developed Chagas disease reactivation (CDR) diagnosed by serum PCR; all were asymptomatic. Median time from transplantation to reactivation was 48 days (range 22-426). Treatment with benznidazole for 60 days cleared the parasitemia in all patients. At 2 years, 80% (8/10) had graft survival, one patient died unrelated to CDR.
conclusionWe report a high incidence of CDR among SOT recipients at a US transplant center serving a predominantly immigrant population, with favorable 2-year outcomes. Most reactivation events occurred early post-transplant, although a later recurrence was also observed. Intensive monitoring for CDR proved effective in detecting reactivation prior to the onset of symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.